What are the rules of industrial transfer of new drug enterprises in the past 10 years? (1)

The research and development of innovative drugs is the driving force to promote the development of the pharmaceutical industry, and it is also the only way for China to move from a big pharmaceutical country to a powerful pharmaceutical country The national "863 Plan", "973 Plan" and "National Science and technology major project" and other policies have given encouragement and support to the research and development of new drugs In recent years, with the return of a large number of scientific and technological innovation talents, capital injection, the improvement of the national new drug review and approval system and the inclusion of the medical insurance catalog into innovative drugs, China's innovative drugs have ushered in a historic development opportunity This paper aims to find out the law of the transfer of innovative pharmaceutical enterprises' foreign investment and relocation in the past 10 years The first part will reveal the current industrial situation of new drug enterprises, and the second part will focus on the analysis of the external radiation and absorption investment of innovative drug enterprises in recent 10 years from the perspective of industrial transfer Please look forward to it 1、 Overview of new drugs refers to the drugs whose chemical structure, drug components and pharmacological effects are different from those of existing drugs The drugs that have changed the dosage form, changed the way of administration and added new indications are not new drugs, but the registration of drugs shall be declared according to the procedure of new drug application In order to ensure the quantity and timeliness requirements of research samples, we adopt an expanded definition for new drug enterprises: the enterprises that have applied for drugs according to the procedures of new drug application in the past 10 years are new drug enterprises Strictly speaking, the number of class I new drugs is relatively small From 2009 to 2018, 38 class I new drugs were approved in China As of December 2018, 40 class I new drug listing applications have been accepted (based on the acceptance number) See Table 1 Figure 1 2009-2018 China approved class I new drugs II Analysis of the current situation of new drug enterprises Based on the flint creation database, we selected 2939 enterprises from the ind application database, clinical trial database, NDA application database, and approved listing database that have registered and applied for new drugs in recent 10 years, including biological drugs (1-15 categories), chemical drugs (1-2 categories) and traditional Chinese medicine (1-8 categories) 1 In the north, Guangsu is the first array, and Zhechuan is the second At the regional level, innovative pharmaceutical enterprises are mainly concentrated in the first tier cities such as Beijing, Shanghai, Jiangsu and Guangdong, and in the eastern coastal developed areas, while in the central and western regions, Sichuan Province has a relatively high concentration Figure 2 distribution of innovative drug enterprises in China's provinces (cities and autonomous regions) the total number of enterprises in top 10 provinces (cities and autonomous regions) accounts for 73% of the total, with a high degree of enterprise concentration; top 10 is successively Beijing, Shanghai, Jiangsu, Guangdong, Zhejiang, Sichuan, Shandong, Jilin, Hubei, Liaoning and Tianjin See Figure 3 Fig 3 the number of innovative drug enterprises in some provinces (cities and autonomous regions) in China 2 The landing is in favor of the provincial capital cities, and the development of urban agglomerations is in its infancy Among the top 20 innovative drug enterprises, 16 are provincial capitals and municipalities directly under the central government, accounting for 80% The key factors for the development of innovative pharmaceutical enterprises are policies, funds and talents, while the provincial capital city is generally the political, economic and talent center of each province Figure 4 distribution of national innovative drug enterprises in cities Figure 5 top 20 cities of the number of innovative drug enterprises in China From the perspective of the degree of urban agglomeration of innovative pharmaceutical enterprises, China's innovative pharmaceutical enterprises have initially formed the Beijing Tianjin wing urban agglomerations with Beijing, Tianjin and Shijiazhuang as the centers, which may extend to South Hebei, Shandong and other places in the future; the Jiangsu Zhejiang Shanghai Urban Agglomerations with Shanghai, Hangzhou, Suzhou and Nanjing as the centers may extend to North Jiangsu, South Zhejiang, Anhui and other places in the future In addition, the urban agglomerations of Guangdong with Guangzhou and Shenzhen as the center, and the urban agglomerations of Sichuan and Chongqing with Chengdu and Chongqing as the center have taken shape and are expected in the future Figure 6 urban distribution of innovative drug enterprises in China figure 3.15-20-year-old enterprises are the backbone, and the industrial development in recent 10 years is more concentrated From the point of view of time, 33% of the innovative pharmaceutical enterprises have been established in 2000-2004 In recent years, the number of enterprises has decreased year by year The reason may be that the enterprise pool includes the enterprises with innovative achievements, while most of the new drug enterprises established in recent 10 years have not yet produced innovative achievements, and most of the innovative drug businesses are cut in on the basis of other businesses Figure 7 year distribution of innovative drug enterprises in China from 1990 to 2018 in 2009-2018, the proportion of the total number of top 20 urban enterprises in the number of new drug enterprises increased from 63% to 78%, suggesting that the agglomeration effect and resource focus of developed cities are more conducive to the output of innovation achievements Figure 8 top 20 cities with the number of newly established innovative drug enterprises in China from 2009 to 2018 in terms of top 10 ranking over the years, Shanghai Super Beijing has become the biggest winner in the development of new drug enterprises (with innovative achievements) in the past 10 years, and Suzhou, Hangzhou, Taizhou and other cities have also increased their ranking to some extent Table 1 the number of newly established innovative drug enterprises in China's top 10 cities in 2009-2018 changes 4 Domestic enterprises dominate, the role of foreign investment is increasingly obvious, and Shanghai and Beijing are far ahead in attracting foreign investment From the perspective of capital structure, innovative pharmaceutical enterprises can be divided into domestic funded enterprises, domestic funded enterprises - foreign investment background (foreign-funded enterprise investment), joint ventures, Taiwan, Hong Kong and Macao enterprises and foreign-funded enterprises, with the number of domestic funded enterprises accounting for 76.7% and foreign-funded enterprises accounting for 23.3% Figure 9 overview of capital structure of national innovative drug enterprises with the continuous opening of policies, the introduction of foreign capital or foreign advanced technology plays an important role in the development of domestic innovative drugs According to the statistics of capital composition of newly established innovative drug enterprises in recent 10 years, it is found that the proportion of foreign-funded, joint-venture and foreign-funded enterprises is increasing, and many international innovative drug giants have completed the layout of R & D or Industrialization Bases in China Shanghai and Beijing are the first choice for foreign capital to choose location and layout in China The total number of enterprises in the two places accounts for 40.7% of all foreign-funded enterprises Figure 10 comparison of the trend of foreign-funded innovative pharmaceutical enterprises in 2009-2018 Figure 11 layout of foreign-funded innovative pharmaceutical enterprises top 10 5 The average output time of innovative achievements has been constantly shortened From the perspective of innovation achievements, the average time from the registration and establishment of enterprises to the first application of innovative drugs in the past 20 years has been shortened from 12.38 to 6.93, with an average increase of about 44%; the proportion of time reduction shows a downward trend With the continuous inclination of policy, capital, talents and other elements, the time interval between the output of innovation achievements will continue to shorten Figure 12 the trend of average time-consuming of innovative products in the past 20 years the number of innovative drug companies in top 10 cities is 6.58 years, 5.1% lower than the average See Figure 13 Figure 13 number of innovative pharmaceutical companies average time consumption of innovative products in top 10 cities 3 Summary Based on the data analysis of the spatial distribution, time distribution, capital composition and innovation achievements of innovative drug enterprises, we find that the current situation of innovative drug enterprises in China is as follows: (1) focusing on the key developed cities, they are moving towards the road of cluster development; (2) establishing innovative drug enterprises for 10-15 years is the backbone of the current market; (3) domestic enterprises are dominant, while foreign enterprises are dominant Continuous increase; (4) the output cycle of results is long and is constantly shortening.